-
Product Insights
NewBetter Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Better Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Better Therapeutics Inc (Better Therapeutics) is a healthcare technology company that develops prescription software for treating cardiometabolic diseases. Better Therapeutics is headquartered in San Francisco, California, the US. GlobalData's Medical Devices company profile report, “Better Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023" provides information about the company overview and analysis on their pipeline products. This company profile report...
-
Product Insights
NewBetters Medical Investment Holdings Ltd Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Betters Medical Investment Holdings Ltd Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Betters Medical Investment Holdings Ltd (Betters Medical Investment) is a medical device manufacturing company. Betters Medical Investment is headquartered in China. GlobalData's Medical Devices company profile report, “Betters Medical Investment Holdings Ltd Pipeline Insight and Competitive Landscape, 2023" provides information about the company overview and analysis on their pipeline products. This company profile report provides key information...
-
Innovation Ranking
Innovation Ranking – Better Life Pharmaceuticals Inc
Better Life Pharmaceuticals Inc (Better Life Pharma), formerly Pivot Pharmaceutical Inc is a biopharmaceutical company that focuses on the development and commercialization of cannabinoid-based nutraceutical and pharmaceutical products. The company’s major product offerings include capsules and tablets, bulk powder, stick packs, beverages, oral solutions, lotions, creams and gels and pet food additives. It develops various technologies for cannabinoids including thrudermic transdermal nanotechnology, Solmic micelle oral drug delivery technology, BiPhasix topical delivery technology, ready-to-infuse cannabis technology and TriVair drug delivery technology....
-
Product Insights
Better Energy Toms Solar PV Project, Poland
Empower your strategies with our Better Energy Toms Solar PV Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough understanding of the project’s core details and stages of development.....
-
Analyst Opinions
NewUnited States (US) Wealth Management – High Net Worth (HNW) Investors
US Wealth Management Report Overview In the US, men dominate the High Net Worth (HNW) space, accounting for more than 82% of HNWs. The situation is slowly evolving, however, with female HNW investors becoming an increasingly attractive target segment. The US wealth management market report analyzes the investment preferences, service requirements, and portfolio allocation of US HNW investors. The report is based on GlobalData’s proprietary Global Wealth Managers Survey. Key Investment Preferences ·      Advisory Asset Management ·      Automated Investment Services...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRGN-3006 in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGN-3006 in Myelodysplastic Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRGN-3006 in Myelodysplastic Syndrome Drug Details: PRGN-3006 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRGN-3006 in Chronic Myelomonocytic Leukemia (CMML)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGN-3006 in Chronic Myelomonocytic Leukemia (CMML) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRGN-3006 in Chronic Myelomonocytic Leukemia (CMML) Drug Details: PRGN-3006...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRGN-3006 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGN-3006 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRGN-3006 in Refractory Acute Myeloid Leukemia Drug Details: PRGN-3006...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRGN-3006 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGN-3006 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRGN-3006 in Relapsed Acute Myeloid Leukemia Drug Details: PRGN-3006...
-
Analyst Opinions
NewIndia Wealth Management – High Net Worth (HNW) Investors
India Wealth Management Market Report Overview The Indian HNW market is dominated by older and professional males. HNW investors have mainly sourced their wealth from earned income; entrepreneurial income and inheritance form smaller yet growing sources. In a highly competitive market such as this, advisory mandates have the highest demand, yet offering a multi-service proposition underpinned by a proven ability to demonstrate returns will be key to tapping into demand. Growing appetite for managed mandates and alternative investments provides arguably...